Table 2.
Use of stem cells in patients with spondyloarthropathies in published literature and registered clinical trials.
| SpA | Stem Cells | Description | Reference |
|---|---|---|---|
| Psoriatic arthritis | Allogenic blood stem cell transplantation (myeloablative) | Concomitant chronic myelogenous leukemia. Graft versus autoimmunity effect. | Slavin et al. [109] |
| Psoriatic arthritis | Allogenic hematopoetic stem cell transplantation | Concomitant aplastic anemia. Short remission with long chronic disability-free period | Woods et al. [110] |
| Psoriatic arthritis | Autologous hematopoetic stem cell transplantation (myeloablative) | Concomitant multiple myeloma. Complete remission of arthritis and skin lesions | Braiteh et al. [111] |
| Ankylosing spondylitis | Autologous hematopoetic stem cell transplantation | Concomitant lymphoma. The patient underwent chemotherapy. Clinical remission for both AS and lymphoma | Jantumen et al. [112] |
| Ankylosing spondylitis | Allogenic blood stem cell transplantation | Concomitant acute myeloid leukemia. The patient underwent chemotherapy and body irradiation. Clinical remission. Partial radiological regression of syndesophytes | Britanova et al. [114] |
| Ankylosing spondylitis | Autologus hematopoetic stem cell transplant | The first reported intentional stem cell transplant for AS. The patient underwent chemotherapy. Complete remission for AS for two-year follow up period | Yang et al. [113] |
| Ankylosing spondylitis | Allogenic mesenchymal stem cells intravenous infusion | Trial involving 31 AS patients. No adverse effects noted. Reduction of ASDAS-CRP from 3.6 ± 0.6 to 2.4 ± 0.5 at the 4th week. The percentage of ASAS 20 responders reached 77.4% | Wanga et al. [115] |
| Ankylosing spondylitis | Human umbilical cord-derived mesenchymal stem cells | Clinical trial. Phase 1. Human umbilical cord-derived MSCs at a dose of 1.0 × 106 MSC/kg, repeated after three months and DMARDs such as sulfasalazine, methotrexate, thalidomide for 12 months |
Clinical Trials. gov Identifier: NCT01420432 [116] |
| Ankylosing spondylitis | Human mesenchymal stem cells | Clinical trial. human mesenchymal stem cells: 1.0 × 104-6 cells/kg, IV on day 1 of each 14–60 day cycle, 1–6 times treatment, plus NSAIDs. |
ClinicalTrials.gov Identifier: NCT01709656 [117] |
| Ankylosing spondylitis | Human bone marrow-derived MSCs | Recruiting clinical trial. Phase 2. hBM-MSCs at a dose of 1.0 × 106 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. Study Start Date: June 2016 Estimated Study Completion Date: December 2018 |
ClinicalTrials.gov Identifier: NCT02809781 [118] |
| Ankylosing spondylitis | Mesenchymal stem cells | Clinical trial. Phase I/II. To observe the safety and clinical effect of MSC transplantation in AS |
Clinical trial. Registration number: ChiCTR-TRC-11001417 [119] |
AS, ankylosing spondylitis; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score Containing C-Reactive Protein; ASAS 20, Assessment in Ankylosing Spondylitis Response Criteria 20; hBM-MSCs, human bone marrow-derived mesenchymal stem cells, DMARDs, disease-modifying anti-rheumatic drugs; NSAIDs, on steroidal anti-inflammatory drugs.